Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP403827.RATzIM0AaXo0tv8IgA7EWZWbhhWNL2OpBJoe6SJCzz_so130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP403827.RATzIM0AaXo0tv8IgA7EWZWbhhWNL2OpBJoe6SJCzz_so130_assertion type Assertion NP403827.RATzIM0AaXo0tv8IgA7EWZWbhhWNL2OpBJoe6SJCzz_so130_head.
- NP403827.RATzIM0AaXo0tv8IgA7EWZWbhhWNL2OpBJoe6SJCzz_so130_assertion description "[We conducted a clinical trial to evaluate bevacizumab, a neutralizing antibody against vascular endothelial growth factor, in patients with metastatic renal-cell carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP403827.RATzIM0AaXo0tv8IgA7EWZWbhhWNL2OpBJoe6SJCzz_so130_provenance.
- NP403827.RATzIM0AaXo0tv8IgA7EWZWbhhWNL2OpBJoe6SJCzz_so130_assertion evidence source_evidence_literature NP403827.RATzIM0AaXo0tv8IgA7EWZWbhhWNL2OpBJoe6SJCzz_so130_provenance.
- NP403827.RATzIM0AaXo0tv8IgA7EWZWbhhWNL2OpBJoe6SJCzz_so130_assertion SIO_000772 12890841 NP403827.RATzIM0AaXo0tv8IgA7EWZWbhhWNL2OpBJoe6SJCzz_so130_provenance.
- NP403827.RATzIM0AaXo0tv8IgA7EWZWbhhWNL2OpBJoe6SJCzz_so130_assertion wasDerivedFrom befree-2016 NP403827.RATzIM0AaXo0tv8IgA7EWZWbhhWNL2OpBJoe6SJCzz_so130_provenance.
- NP403827.RATzIM0AaXo0tv8IgA7EWZWbhhWNL2OpBJoe6SJCzz_so130_assertion wasGeneratedBy ECO_0000203 NP403827.RATzIM0AaXo0tv8IgA7EWZWbhhWNL2OpBJoe6SJCzz_so130_provenance.